logo
Twitter
Discord
Email
logo
Sight Sciences, Inc.

Sight Sciences, Inc.

NASDAQ•SGHT
CEO: Mr. Paul Badawi
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2021-07-15
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Contact Information
4040 Campbell Avenue, Suite 100, Menlo Park, CA, 94025, United States
877-266-1144
www.sightsciences.com
Market Cap
$342.08M
P/E (TTM)
-7.3
32.4
Dividend Yield
--
52W High
$9.24
52W Low
$2.03
52W Range
62%
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2025 Data

Revenue

$19.91M-1.24%
4-Quarter Trend

EPS

-$0.16-27.27%
4-Quarter Trend

FCF

-$8.89M-1719.13%
4-Quarter Trend

Earnings Highlights

Key Highlights

No Data Available

Risk Factors

No Data Available

Outlook

No Data Available

Peer Comparison

Revenue (TTM)

Owlet, Inc.OWLT
$99.66M
+26.8%
Sight Sciences, Inc.SGHT
$76.05M
-4.4%
Prenetics Global LimitedPRE
$69.04M
+171.7%

Gross Margin (Latest Quarter)

MaxCyte, Inc.MXCT
92.4%
+16.1pp
Sight Sciences, Inc.SGHT
86.4%
+2.5pp
TriSalus Life Sciences, Inc.TLSI
83.5%
-2.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
FBRX$418.27M-11.5-75.6%0.0%
SGHT$342.08M-7.3-61.6%35.0%
PROF$248.26M-6.3-86.8%0.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.4%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 4, 2026
|
EPS:-$0.17
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $19.91M-1.2%
    |
    EPS: $-0.16-27.3%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $19.56M-8.5%
    |
    EPS: $-0.23-8.0%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $17.51M-9.1%
    |
    EPS: $-0.28-15.2%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 7, 2025|
    Revenue: $79.87M-1.5%
    |
    EPS: $-1.03+9.6%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $20.16M+0.7%
    |
    EPS: $-0.22-18.5%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 2, 2024|
    Revenue: $21.37M-9.0%
    |
    EPS: $-0.25-16.7%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 6, 2024|
    Revenue: $19.27M+2.3%
    |
    EPS: $-0.33-5.7%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 13, 2024|
    Revenue: $81.06M+13.6%
    |
    EPS: $-1.14+36.7%
    Miss